Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group B vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal group B vaccine (rMenB) is a recombinant protein-based vaccine used to prevent invasive disease caused by *Neisseria meningitidis* serogroup B. The vaccine contains several antigenic components including factor H binding protein (fHbp), Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA), and an outer membrane vesicle (OMV) containing PorA P1.4 from the NZ98/254 strain[6][8]. These antigens are designed to stimulate the immune system to produce bactericidal antibodies against diverse strains of serogroup B meningococcus[6][8]. The primary indication is for immunization of individuals aged 10–25 years at increased risk for serogroup B meningococcal disease[1][4]. rMenB does not treat active infection but provides prophylactic immunity.
- Brand names
- BexseroTrumenba
- Other names
- MenBrMenB-OMVrecombinant meningococcal group B vaccine
02
Targets
fHbp (Factor H-binding protein)NHBA (Neisserial heparin-binding antigen)NadA (Neisserial adhesin A)PorB (Major outer membrane porin PorB)LOS (Lipooligosaccharide)
Beyond the preview
Go deeper on meningococcal group B vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group B vaccine.